e-learning
resources
Vienna 2012
Tuesday, 04.09.2012
Treatment of lung cancer
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
TTF-1 for prediction of response to chemotherapy in patients with locally advanced or metastatic small cell lung cancer (SCLC)
D. Misch, J. Kollmeier, T. Blum, S. Griff, C. Boch, T. Weiss, C. Crolow, W. Grüning, T. Mairinger, T. Bauer (Berlin, Germany)
Source:
Annual Congress 2012 - Treatment of lung cancer
Session:
Treatment of lung cancer
Session type:
Oral Presentation
Number:
3267
Disease area:
Thoracic oncology
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
D. Misch, J. Kollmeier, T. Blum, S. Griff, C. Boch, T. Weiss, C. Crolow, W. Grüning, T. Mairinger, T. Bauer (Berlin, Germany). TTF-1 for prediction of response to chemotherapy in patients with locally advanced or metastatic small cell lung cancer (SCLC). Eur Respir J 2012; 40: Suppl. 56, 3267
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ICU admission of lung cancer patients – Is COVID-19 a game-changer?
Surgical vs non-surgical treatment of early stage non-small cell lung cancer: here's the fight
N3 hilar sampling decision in the staging of mediastinal lung cancer
Related content which might interest you:
Should patients with metastatic NSCLC and poor performance status be treated by chemotherapy?
Source: Annual Congress 2007 - Treatment of metastatic nonsmall cell lung cancer in the era of targeted therapies
Year: 2007
24h-blood profile gene expression biomarkers of the response to bevacizumab-erlotinib (BE) in advanced non-squamous non-small cell lung cancer (NSCLC)
Source: International Congress 2016 – Therapeutic trials in lung cancer
Year: 2016
Neo-adjuvant chemotherapy: level of evidence in early stage and in marginally resectable disease
Source: Annual Congress 2005 - Multidisciplinary treatment of non-metastatic non-small cell lung cancer: contemporary concepts
Year: 2005
Hyper-progressive disease in patients with advanced non-small cell lung cancer (NSCLC) treated with nivolumab (nivo)
Source: International Congress 2018 – Lung cancer: modern therapies and beyond
Year: 2018
Pulmonary re-biopsy in non–small-cell lung cancer (NSCLC) locally advanced or metastatic with EGFR-T790M resistance.
Source: International Congress 2018 – Bronchoscopy and transthoracic ultrasound
Year: 2018
The comparison of paclitaxel-carboplatin (PCp) versus gemcitabine-cisplatin (GC) in the treatment of locally advanced or metastatic non-small cell lung cancer
Source: Eur Respir J 2002; 20: Suppl. 38, 464s
Year: 2002
Impact of neoadjuvant therapy on tumor resectability and survival of patients with locally advanced non-small cell lung cancer
Source: Annual Congress 2011 - General thoracic surgery II
Year: 2011
MDM-2 gene amplification is associated with poor prognosis in operable non-small cell lung cancer (NSCLC)
Source: Eur Respir J 2002; 20: Suppl. 38, 596s
Year: 2002
How to treat brain metastasis in patients with non-small cell lung carcinoma (NSCLC) and EGFR mutations
Source: International Congress 2015 – How to treat brain metastases
Year: 2015
Is Cyfra 21-1 serum level predictive for the type of response to treatment or survival in locally advanced and metastatic non-small cell lung cancer (NSCLC)?
Source: Eur Respir J 2004; 24: Suppl. 48, 76s
Year: 2004
Should there be a specific management for large cell neuroendocrine carcinoma?
Source: Annual Congress 2005 - Neuroendocrine tumours of the lung
Year: 2005
Stage I-IIIa small cell lung cancer (SCLC): multimodal therapy including surgery
Source: Eur Respir J 2001; 18: Suppl. 33, 318s
Year: 2001
p53 mutations do not predict response to paclitaxel in metastatic non-small cell lung carcinoma
Source: Annual Congress 2009 - Lung cancer biology
Year: 2009
The influence of secondary infectious process on non-small cell lung cancer (NSCLC) patients survival
Source: Eur Respir J 2007; 30: Suppl. 51, 280s
Year: 2007
The role of palliative radiotherapy in locally advanced non small cell lung cancer
Source: Annual Congress 2007 - Therapy of lung cancer
Year: 2007
Trends in drug costs and overall survival in patients diagnosed with metastatic non-small cell lung cancer (NSCLC)
Source: International Congress 2019 – How to guide patients to reach a balance between costs and personal needs: quality indicators of effectiveness
Year: 2019
Serum tumor markers and quality of life before and after platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patients
Source: Eur Respir J 2002; 20: Suppl. 38, 74s
Year: 2002
How to predict fatal pneumonitis in non-small cell lung cancer (NSCLC) patients treated with radiotherapy (RT)
Source: International Congress 2018 – Lung cancer: modern therapies and beyond
Year: 2018
Chemotherapy in advanced non small cell lung cancer
Source: Eur Respir J 2005; 26: Suppl. 49, 77s
Year: 2005
Treatment of advanced non-small cell lung cancer
Source: Annual Congress 2005 - PG2 - Lung cancer: non-small cell lung cancer treatment
Year: 2005
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept